EpiBiologics emerges with $50m and protein degradation platform
The biotech is launched with an antibody-based protein degradation platform, with technology licensed from UCSF.
Source: biopharma-reporter.com
Stay updated with breaking news from Epibiologic Epi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biotech is launched with an antibody-based protein degradation platform, with technology licensed from UCSF.